Continuous Glucose Monitoring Clinical Trial
Official title:
Markers for Glycaemic Control and Continuous Glucose Monitoring in Persons With Type 2 Diabetes on Peritoneal Dialysis
The aim is to investigate the correlation between mean glucose measured by continuous glucose monitoring (CGM) and mean glucose estimated from glycated haemoglobin A1c (HbA1c) in persons with type 2 diabetes undergoing peritoneal dialysis compared with patients with type 2 diabetes and normal renal function. Furthermore, the aim is to compare CGM and HbA1c with glycated albumin and fructosamine.
Background:
In persons with type 2 diabetes, glycated haemoglobin A1c (HbA1c) is used as an indirect
measure of the mean glucose over the past 3-4 months. The normal range of HbA1c and the
correlation to the mean glucose has been determined from studies in subjects without severe
chronic kidney disease.
In persons with end-stage renal disease (ESRD) and type 2 diabetes, HbA1c has been shown in
small studies to underestimate mean glucose when compared with continuous glucose monitoring
(CGM) or alternative glycaemic markers such as glycated albumin or fructosamine. The cause of
a falsely low HbA1c in persons with ESRD and diabetes is not clear, but adjuvant
erythropoietin treatment and iron infusion increase erythropoiesis, thus increasing the
number of new non-glycated erythrocytes that are thought to lower HbA1c. Furthermore, the
erythrocyte life span was found to be decreased in individuals receiving hemodialysis and
peritoneal dialysis, which may also contribute to a reduction in HbA1c.
CGM is an alternative to HbA1c in glycaemic monitoring and measures interstitial glucose that
calibrates with blood glucose within minutes. CGM measures interstitial glucose every five
minutes for up to eight days (Medtronic's Ipro2). Studies of persons with type 1 diabetes and
CGM measurements performed over three months showed that approximately two-weeks of CGM
measurements correlated to HbA1c. When CGM was performed beyond 14 days, the correlation
between the mean glucose from CGM and HbA1c improved only modestly.
Values of CGM measurements also provide a basis for monitoring glycaemic variability,
time-in-range and hypoglycaemic episodes. For persons with diabetes undergoing peritoneal
dialysis, there are only a few studies validating HbA1c and none have been prospective with a
control group over a long period of time. A retrospective study of 60 persons with diabetes
and in peritoneal dialysis (without control group) found a significant correlation between
HbA1c and mean interstitial glucose as measured by CGM (r = 0.48, P≤0.0001). A prospective
study of 25 persons with diabetes and in peritoneal dialysis (without control group) also
found a significant correlation (r = 0.51, P≤0.01). A study of three persons with diabetes
and in peritoneal dialysis (without control group) found that HbA1c compared to CGM
underestimated mean glucose in one, but overestimated mean glucose in the other two. However,
all three studies did not include a control group and had few days of CGM measurements, which
collectively mean that the evidence for the use of HbA1c in this patient group is sparse.
In a study of peritoneal dialysis subjects with diabetic nephropathy (n = 1296), 17.7% had
normal HbA1c and were without antidiabetic treatment. When the same study included glycated
albumin, 10.9% were found to have normal HbA1c, normal glycated albumin (defined as less than
16%) and were without antidiabetic medication. The study concluded that normal HbA1c alone
overestimates the prevalence of burnt-out diabetes.
The uncertainty associated with HbA1c in persons with type 2 diabetes undergoing peritoneal
dialysis is a problem both in terms of diagnosing and treating diabetes appropriately. CGM,
glycated albumin and fructosamine are independent of erythrocyte turnover thus allowing for a
validation of HbA1c in this group of patients.
Objective:
To investigate the correlation between mean glucose measured by continuous glucose monitoring
(CGM) and mean glucose estimated from glycated haemoglobin A1c (HbA1c) in persons with type 2
diabetes undergoing peritoneal dialysis compared with a control group of persons with type 2
diabetes and normal renal function.
Method:
Prospective case-control study over 16 days with 26 persons in each group. The case group
consist of persons with type 2 diabetes undergoing peritoneal dialysis and the control group
consists of persons with type 2 diabetes with normal renal function (defined as an estimated
glomerular filtration rate (eGFR) above 60 ml/min and urine albumin-creatinine ratio below
300mg/g). CGM is performed for a maximum of 16 days. On visit 1 (day 0), CGM is performed for
8 days and visit 2 (day 8) (+7/-4 days), CGM is performed for another 8 days. Glycaemic
markers are measured at baseline and on visit 3 (final day of the study). At least 12 days of
CGM must be completed for each person. Data is collected using REDcap.
Statistics:
The null hypothesis is that there is no difference in the ratio between the two groups
measured as mean glucose concentration measured over 16 days at CGM (mmol / L) divided by the
estimated glucose concentration from HbA1c (mmol / L) measured at day 16.
The alternative hypothesis is that there is a 17% difference between groups for the ratio of
mean glucose concentration measured by CGM (mmol / L) divided by the mean glucose
concentration from HbA1c (mmol / L). In a pilot study of persons with type 2 diabetes and
dialysis dependent ESRD compared with persons with normal renal function, a 17% difference
was found in the ratio between the two groups. In a two-sided unpaired t-test with α = 0.05,
SD = 1.17 and power of 90%, a sample size of 24 individuals in each group will show a
significant difference. A drop of approximately 10% is expected and a total of 26 are
included in each group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04099043 -
Cascade CGM 15-day Performance Assessment
|
N/A | |
Recruiting |
NCT05441982 -
Saccharin and Acesulfame Potassium Consumption and Glucose Homeostasis in Older Adults With Prediabetes
|
N/A | |
Completed |
NCT05038761 -
A Study to Learn How Well a Monitoring System Called Continuous Glucose Monitoring (CGM) Which Measures Glucose on an Ongoing Basis Works and How Safe it is in Chinese Patients in Usual Practice
|
||
Completed |
NCT01714895 -
Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring
|
N/A | |
Not yet recruiting |
NCT05531838 -
Prediabetes Management
|
N/A | |
Active, not recruiting |
NCT06226948 -
Using the Visualization for Lifestyle Change in Patients at Risk of Cardiovascular Diseases
|
N/A | |
Completed |
NCT05348928 -
A Pilot Study of the Feasibility and Accuracy of the TrueVie CGM System - A Non-Significant Risk Study
|
||
Active, not recruiting |
NCT05336214 -
Implementing Continuous Glucose Monitoring in Primary Care for Patients With Diabetes
|
N/A | |
Terminated |
NCT03067480 -
Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients
|
N/A | |
Completed |
NCT04558710 -
The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes
|
||
Withdrawn |
NCT04385862 -
The Use of a Continuous Glucose Monitoring System (Dexcom G6) in Hospitalized Patients for Acute Care
|
||
Not yet recruiting |
NCT06436326 -
The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes
|
N/A | |
Not yet recruiting |
NCT04172116 -
Continuous Glucose Monitoring (CGM) After Surgical Variations of the Roux-en-y Gastric Bypass
|
||
Completed |
NCT01883622 -
Glucose Variability in Pregnancy Complicated by Diabetes
|
N/A | |
Recruiting |
NCT05947916 -
Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy
|
N/A | |
Active, not recruiting |
NCT05564481 -
Research on Optimizing the Use of Technology With Education
|
N/A | |
Recruiting |
NCT06400641 -
Study on the Feasibility of Continuous Glucose Monitoring(CGM) for Improving Blood Glucose Control in Severe Patients
|
||
Recruiting |
NCT04099550 -
Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes
|
N/A | |
Not yet recruiting |
NCT04397965 -
Cascade Continuous Glucose Monitor (CGM) 15-Day US Performance Assessment
|
N/A | |
Completed |
NCT02942069 -
Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring
|